- Home
- TARS vs DBD Comparison
TARS vs DBD Comparison
Compare TARS & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- DBD
- Stock Information
- Founded
- TARS 2016
- DBD 1859
- Country
- TARS United States
- DBD United States
- Employees
- TARS N/A
- DBD N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- DBD EDP Services
- Sector
- TARS Health Care
- DBD Technology
- Exchange
- TARS Nasdaq
- DBD Nasdaq
- Market Cap
- TARS 1.7B
- DBD 1.9B
- IPO Year
- TARS 2020
- DBD N/A
- Fundamental
- Price
- TARS $41.13
- DBD $59.27
- Analyst Decision
- TARS Strong Buy
- DBD Strong Buy
- Analyst Count
- TARS 7
- DBD 2
- Target Price
- TARS $67.14
- DBD $65.00
- AVG Volume (30 Days)
- TARS 594.1K
- DBD 302.7K
- Earning Date
- TARS 08-07-2025
- DBD 08-06-2025
- Dividend Yield
- TARS N/A
- DBD N/A
- EPS Growth
- TARS N/A
- DBD N/A
- EPS
- TARS N/A
- DBD N/A
- Revenue
- TARS $233,674,000.00
- DBD $3,696,800,000.00
- Revenue This Year
- TARS $122.94
- DBD $2.02
- Revenue Next Year
- TARS $44.14
- DBD $1.96
- P/E Ratio
- TARS N/A
- DBD N/A
- Revenue Growth
- TARS 449.03
- DBD N/A
- 52 Week Low
- TARS $20.08
- DBD $34.38
- 52 Week High
- TARS $57.28
- DBD $59.99
- Technical
- Relative Strength Index (RSI)
- TARS 43.15
- DBD 86.56
- Support Level
- TARS $38.52
- DBD $55.26
- Resistance Level
- TARS $41.48
- DBD $59.99
- Average True Range (ATR)
- TARS 1.51
- DBD 1.06
- MACD
- TARS 0.12
- DBD 0.48
- Stochastic Oscillator
- TARS 48.21
- DBD 95.90
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.